J
Jean-Jacques Grob
Researcher at Aix-Marseille University
Publications - 369
Citations - 58038
Jean-Jacques Grob is an academic researcher from Aix-Marseille University. The author has contributed to research in topics: Medicine & Melanoma. The author has an hindex of 71, co-authored 310 publications receiving 45788 citations. Previous affiliations of Jean-Jacques Grob include University of Sydney.
Papers
More filters
Algorithme thérapeutique lymphomes T cutanés
Hervé Bachelez,Martine Bagot,Marie Beylot-Barry,Alain Claudy,Florent Grange,Jean-Jacques Grob,Olivier Dereure,Brigitte Dréno,Michel d’Incan,Liliane Laroche,Roland Viraben +10 more
Proceedings ArticleDOI
604 First-line avelumab treatment in patients with metastatic Merkel cell carcinoma: 4-year follow-up from the JAVELIN Merkel 200 trial
Sandra P. D'Angelo,Céleste Lebbé,Laurent Mortier,Andrew S. Brohl,Nicola Fazio,Jean-Jacques Grob,Natalie Prinzi,Glenn J. Hanna,Jessica C. Hassel,Felix Kiecker,Anja von Heydebreck,Gülseren Güzel,Paul Nghiem +12 more
TL;DR: Avelumab as mentioned in this paper was used as a first-line treatment for metastatic Merkel cell carcinoma (mMCC), a rare and aggressive neuroendocrine skin carcinoma.
Journal ArticleDOI
Epacadostat Plus Pembrolizumab versus Placebo Plus Pembrolizumab in Patients with Unresectable or Metastatic Melanoma: Results of the Phase 3, Randomised, Double-Blind Echo-301/Keynote-252 Study
Georgina V. Long,Reinhard Dummer,Omid Hamid,Thomas F. Gajewski,Christian Caglevic,Stéphane Dalle,Ana Arance,Matteo S. Carlino,Jean-Jacques Grob,Tae Min Kim,Lev V. Demidov,Caroline Robert,James Larkin,James R. Anderson,Janet Maleski,Mark M. Jones,Scott J. Diede,Tara C. Mitchell +17 more
TL;DR: For example, Epacadostat, an indoleamine 2,3-dioxygenase 1 (IDO1) selective inhibitor, and pembrolizumab, a programmed death protein (PD)-1 inhibitor, showed promising antitumour activity in the phase 1/2 ECHO-202/KEYNOTE-037 advanced melanoma study as discussed by the authors.
Journal ArticleDOI
Abstract CT002: KEYMAKER-U02 substudy 02C: neoadjuvant pembrolizumab (pembro) + vibostolimab (vibo) or gebasaxturev (geba) or pembro alone followed by adjuvant pembro for stage IIIB-D melanoma
Reinhard Dummer,Caroline Robert,Richard A. Scolyer,Janis M. Taube,Michael T. Tetzlaff,Andrew F. Hill,Jean-Jacques Grob,David Craig Portnoy,Céleste Lebbé,Muhammad A. Khattak,G. Bar-Sela,Inderjit Mehmi,Ronnie Shapira Frommer,Nicolas Meyer,Yixin Ren,Mizuho Fukunaga-Kalabis,Clemens Krepler,Georgina V. Long +17 more
TL;DR: The phase 1/2 KEYMAKER-U02 substudy 02C (NCT04303169) as mentioned in this paper evaluated patients with stage IIIB-D melanoma.
Journal ArticleDOI
Pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: Final analysis of distant metastasis-free survival in the phase 3 KEYNOTE-716 study.
Jason J. Luke,Paolo A. Ascierto,Muhammad A. Khattak,L. de la Cruz Merino,M. Del Vecchio,Piotr Rutkowski,Francesco Spagnolo,Jacek Mackiewicz,Vanna Chiarion-Sileni,John M. Kirkwood,Caroline Robert,Jean-Jacques Grob,Federica De Galitiis,Dirk Schadendorf,G. Carlino,Larry Wu,Mizuho Fukunaga-Kalabis,Clemens Krepler,Alexander M M Eggermont,Georgina V. Long +19 more
TL;DR: Adjuvant pembrolizumab significantly improved distant metastasis-free survival (DMFS) and recurrence free survival (RFS) in patients with resected stage IIB or IIC melanoma versus placebo as discussed by the authors .